Table 4 of
Gushansky, Mol Vis 2024; 30:489-496. Table 4 of
Gushansky, Mol Vis 2024; 30:489-496.
Table 4. Logistic regression analysis adjusted for age, gender, and vaccination status among 1165 SARS-CoV-2 hospitalized patients.
| Multivariate analysis of risk factors | Odds ratio | 95% CI | p-value | |
|---|---|---|---|---|
| Demographics | Age | 1.000 | (0.990, 1.010) | 0.958 |
| Female gender | 0.967 | (0.686, 1.363) | 0.847 | |
| Vaccination | Vaccinated | 1.023 | (0.725, 1.443) | 0.896 |
| Antiemetics | Metoclopramide | 13.413 | (6.288, 28.609) | <0.001 |
| Domperidone | 5.929 | (0.797, 44.082) | 0.082 | |
| Any antiemetic | 2.342 | (5.070, 21.353) | <0.001 | |
| Laxatives | Lactulose | 1.939 | (1.133, 3.316) | 0.016 |
| PEG | 2.094 | (1.150, 3.801) | 0.015 | |
| Bisacodyl | 0.573 | (0.254, 1.289) | 0.178 | |
| Any laxative | 1.257 | (0.775, 2.039) | 0.354 | |
| PPIs | Omeprazole | 0.332 | (0.199, 0.553) | <0.001 |
| Lansoprazole | 0.185 | (0.025, 1.384) | 0.100 | |
| Esomeprazole | 1.354 | (0.706, 2.595) | 0.362 | |
| Any PPI | 0.318 | (0.209, 0.483) | <0.001 | |
| Secondary bile acids | UDCA | 4.666 | (0.612, 35.568) | 0.137 |
| Total drugs | Seven or more | 1.733 | (1.106, 2.717) | 0.017 |